Cardiology Conference: “Practice-Changing” Data On Device Interventions
This article was originally published in The Gray Sheet
Executive Summary
Late-breaking clinical trials of coronary stent and related interventions are bringing both practice-changing and surprising results, according to physicians who attended a major cardiology meeting in Chicago last week
You may also be interested in...
New Products In Brief
Bausch & Lomb gets approval for first-of-a-kind intraocular lens. Roche HbA1c assay is first to be cleared to diagnose diabetes. More product launches and approvals from the past week.
Research In Brief
Drug-coated angioplasty balloon: Percutaneous treatment of femoropopliteal disease with paclitaxel-coated angioplasty balloons was associated with reduced six-month lumen loss and target-lesion revascularization rates compared to regular angioplasty balloons in the 154-patient randomized THUNDER trial sponsored by Bavaria Medizintechnologie and Schering. Results appear in the Feb. 14 issue of the New England Journal of Medicine. THUNDER is a small preliminary study and larger trials are needed to confirm the benefits of drug-coated balloons, according to authors Gunnar Tepe, M.D., University of Tübingen, et al
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.